Eurocine Vaccines is publically listed at Spotlight Stock Market XSAT, Sweden, with the ticker EUCI.
To be notified with news, sign up to our newsfeed =>
Legal Advisor is Lindahl and MCL.
Sedermera is our Financial Advisor.
Patent and Intellectual Property (IP) advisors are Zacco and AWA.
Extraordinary General Meeting 18 March 2024
Below follow documents related to the Extraordinary General Meeting on the 18 March 2024:
Complete Proposed Decisions (Fullständiga beslutsförslag, in Swedish)
Proxy Form (Fullmaktsformulär, in Swedish)
Preferential Unit Issue / Företrädesemission
Eurocine Vaccines gästade Småbolagspodden / Eurocine Vaccines visited the Small Companies´ pod
I samband med den pågående företrädesemission så gästade Eurocine Vaccines vd Hans Arwidsson Småbolagspodden för att berätta mer om bolagets senaste strategiska förändring och utvecklingen av den terapeutiska vaccinkandidaten mot Herpes simplexvirus typ 2 (HSV-2). Lyssna på Eurocine Vaccines i Småbolagspodden !
In connection with the ongoing rights issue, Eurocine Vaccines CEO Hans Arwidsson visited the Småbolagspodden to tell more about the company’s latest strategic change and the development of the therapeutic vaccine candidate against Herpes simplex virus type 2 (HSV-2). Listen to Eurocine Vaccines in the Small Companies´ pod (in Swedish)!
Read the Memorandum and the Teaser!
Eurocine Vaccines AB publishes an Information Memorandum in connection with the Company´s preferential issue of units, up to cirka 7.5 MSEK before issue costs. The subscription period begins Tuesday 9 January 2024.
Eurocine Vaccines´ Memorandum 2024 (in Swedish)
Eurocine Vaccines´ Teaser – a short information brochure (in Swedish). Please read the Important information (Viktig information)!
Terms and conditions for warrants TO 5 – Villkor för teckningsoptioner TO 5 (in Swedish).
Annual General Meeting 29 December 2023
Below follow documents related to the Annual General Meeting on the 29 December 2023:
Complete Proposed Decisions (Fullständiga beslutsförslag, in Swedish)
Presentation of proposed board director (Presentation av föreslagen ledamot, in Swedish)
Annual Report 2022-2023 (Årsredovisning 2022-2023, in Swedish)
Proxy Form (Fullmaktsformulär, in Swedish)
Preferential Share Issue
Eurocine Vaccines AB publishes an Information Memorandum in connection with the Company´s preferential issue of shares up to cirka 9,7 MSEK before issue costs, which subscription period begins Wednesday 2 August 2023.
Eurocine Vaccines´ Memorandum 2023 (in Swedish)
Supplementary Memorandum 7 August 2023 (Tilläggsmemorandum, in Swedish)
Extraordinary General Meeting
26 July 2023
Below follow documents related to the Extraordinary General Meeting on the 26 July 2023:
Complete Proposed Decisions (Fullständiga beslutsförslag, in Swedish)
Proxy Form (Fullmaktsformulär, in Swedish)
Latest Investor Presentation
Future Financial Reports
The Interim Report July 2023 – March 2024 is planned to be available 30 May 2024.
Existing Financial Reports
Interim Report July – December 2023
Interim Report July – September 2023
Annual Report 2022 – 2023 (Swedish)
Full Year Report July 2022 – June 2023
Interim Report July 2022 – March 2023
Interim Report July – December 2022
Interim Report July – September 2022
Full Year Report July 2021 – June 2022 =>
Interim Report July 2021 – March 2022 =>
Interim Report July – December 2021 =>
Interim Report July – September 2021 =>
Full Year Report July 2020 – June 2021 =>
Interim Report July 2020 – March 2021 =>